ProMIS Neurosciences (TSX:PMN), (NASDAQ:PMN) focuses on discovering and developing treatments targeting neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and Parkinson's disease. This company aims to identify specific epitopes on misfolded proteins which are common in these conditions, leveraging their proprietary technology platforms to create both therapeutic and diagnostic solutions. Their portfolio includes several antibody candidates in preclinical development, designed to target toxic misfolded protein aggregates believed to contribute to the progression of neurodegenerative diseases. The ultimate objective of ProMIS Neurosciences is to halt disease progression and improve the quality of life for patients suffering from these devastating conditions.